Compare Adaptive Biotechnologies Corp (ADPT) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Vertiv Holdings Co — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Vertiv Holdings Co trades at $312 (market cap $117.38B). The key difference: Vertiv Holdings Co is far larger — about 35.2× Adaptive Biotechnologies Corp's market cap, and Vertiv Holdings Co pays a 0.08% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | VRT | |
|---|---|---|
Market Cap | $3.33B | $117.38B |
Sector | Health | Technology |
52-Week High | $22.37 | $376.23 |
52-Week Low | $10.24 | $120.72 |
Enterprise Value | $3.19B | $118.14B |
Dividend Yield | — | 0.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Vertiv Holdings (VRT) trades at $318.47, up 5.97% with strong bullish momentum. The stock shows robust fundamentals with Q1 2026 EPS beating estimates at $1.17 versus $1.00 expected, continuing a pattern of earnings outperformance. Technical indicators signal bullish momentum with the current price near pivot point resistance at $319. The company benefits from AI infrastructure demand, supported by recent manufacturing expansion in Malaysia and strategic acquisitions enhancing its data center portfolio.
Outlook remains positive with 94.7% analyst buy ratings and a $395.23 consensus price target implying 24% upside. Key risks include premium valuation multiples (P/E 80.02) and execution challenges in scaling operations. The AI infrastructure boom presents significant growth opportunity, though investors should monitor competitive pressures and macroeconomic conditions affecting data center spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
